Audentes Therapeutics initiated with a Sell at B. Riley FBR. B. Riley FBR analyst Madhu Kumar started Audentes Therapeutics with a Sell rating and $20 price target. A modest market size opportunity and clinical data suggest the shares are overvalued, Kumar tells investors in a research note.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.